Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Revance to Participate in the William Blair 42nd Annual Growth Stock Conference


Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago. Chief Executive Officer, Mark Foley, is scheduled to present on Monday, June 6, at 2:00 p.m. CT / 3:00 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.

About Revance Therapeutics, Inc.

Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPULtm Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.


These press releases may also interest you

at 11:45
In the Hype Cycle for Privacy, 2021, Gartner recognized Prime Factors among Sample Vendors in Privacy, a space that is a top priority for security and risk management leaders managing technology, information and resilience risk. For Format-Preserving...

at 11:15
The Boulder Group announced the release of its 2nd Quarter Net Lease Research Report today. Cap rates in the single tenant net lease sector increased slightly or were unchanged in the second quarter of 2022. Single tenant cap rates increased by 5 and...

at 10:27
Peng Liyuan, wife of Chinese President Xi Jinping, on Thursday visited the Xiqu Center in Hong Kong's West Kowloon Cultural District, a venue for the art of Chinese traditional theater. She watched rehearsals of Cantonese opera performances and a...

at 09:10
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI)...

at 08:04
The...

at 07:55
AUO today announced that it has been recognized by the Manufacturing Leadership Awards (MLA) in categories of Digital...



News published on 23 may 2022 at 08:10 and distributed by: